News
Copenhagen, Denmark, 12 August 2021 – Draupnir Bio (“Draupnir”), a biotechnology company developing small molecule modulators of PCSK9 to transform the treatment of heart disease, today announces an expansion of its operations with the opening of a new research facility at INCUBA Skejby, a leading life sciences development cluster in Aarhus, Denmark.
INCUBA is a state-of-the-art science park and professional community, consistingof around 200 startups, scaleups and established companies and more than 1,500 employees, researchers, entrepreneurs, investors, and specialists. INCUBA Skejby, the healthcare arm of the park, sits within Business Park Skejby, one of Denmark's most knowledge-intensive areas within the health sector. The dynamic environment of the emerging biotech cluster that includes Aarhus University Hospital provides many opportunities for business development and collaboration.
The new site provides Draupnir with the required facilities to support the Company’s preclinical research organisation and the advancement of its innovative pipeline of small molecule therapeutics, as well as expanding capacity to enable future growth. Draupnir is headquartered in Copenhagen.
"
Our new research facility at INCUBASkejby gives us everything we need to continue to grow as a company in our own dedicated incubator space. INCUBA Skejby is an established park which offers a network of experts within the health sector, being home to many other leading life science companies who share a collaborative spirit. We’re looking forward to this next chapter in our company’s development as we push towards transforming the treatment of heart disease
Andrew Hotchkiss, Chief Executive Officer
For more information, please contact:
Draupnir Bio
Andrew Hotchkiss, Chief Executive Officer
info@draupnir.bio
Consilium Strategic Communications
David Daley, Genevieve Wilson, Kumail Waljee
Phone: +44 (0)20 3709 5700
Email: draupnirbio@consilium-comms.com
